NCT01849848 · REGISTRY CONDITION SEARCH

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2015-02-06

The purpose of this study is to determine the antitumor efficacy and safety of bendamustine (SyB L-0501: 90 mg/m\^2/day) for a maximum of 6 cycles (1 cycle: intravenous administration for 2 consecutive days and 26-day observation period) in patients with relapsed/refractory multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria

→

outcome · POSTED

Response Rate (sCR+CR) Based on IMWG Criteria

→

outcome · POSTED

Complete Response (CR) Based on the Blade Criteria

→

outcome · POSTED

Response Rate (CR+PR) Based on the Blade Criteria

→

outcome · POSTED

Progression-Free Survival (PFS)

→

outcome · POSTED

Time to Treatment Failure (TTF)

→

outcome · POSTED

Duration of Response (DOR)

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Adverse Events

→

outcome · POSTED

Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values

→

outcome · POSTED

Number of Abnormalities (Grade ≥3) in Laboratory Test Values

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Patients who are diagnosed with multiple myeloma on the basis of the response criteria of the International Myeloma Working Group (IMWG) and confirmed to meet one or more of the following criteria: (definition of progression according to the IMWG response criteria) * 25% or more increase compared to baseline for the following values * Serum M-protein level (however, the absolute value is 0.5 g/dL or higher) * Urine M-protein level (however, absolute value is 200 mg/24 hours or higher) * For lesions without measurable serum or urine M-protein values. involved/uninvolved free light chain (FLC) ratio (however, absolute value is 10 mg/dL or higher) * Clear appearance of new bone lesions or soft tissue plasmacytoma or apparent growth in size of current bone lesions or soft tissue plasmacytoma * Appearance of hypercalcemia (corrected calcium level ≥ 11.5 mg/dL and if determined to be caused solely by myelomas) 2. Patients with measurable lesions (meets at least one of the following two criteria * Serum M-protein \[Immunoglobulin G (IgG)≥ 1.0 g/dL, Immunoglobulin A (IgA) ≥ 0.5 g/dL, Immunoglobulin D (IgD) ≥ 0.1 g/dL) * Urine M-protein ≥ 200 mg/24 hours 3. Patients who meet either one of the following items for all prior chemotherapy using proteasome inhibitors, Immunomodulatory Drugs (IMiDs) (thalidomide or lenalidomide) or alkylating agents. * No response\* * Relapse/recurrence after response\* * Intolerance * Not applicable (reason can be confirmed in the source document) because of predicted aggravation of complications (neurotoxicity, etc.) \* Patients whose disease has progressed based on the IMWG response criteria after receiving the most recent therapy 4. Patients who have undergone a washout period of more than 3 weeks after the end of the previous therapy and determined not to be under the effect of previous treatment (antitumor effectiveness). 5. Patients who are expected to survive for at least 3 months 6. Patients aged from 20 to 79 years at the time of interim registration 7. Performance Status (P.S.) of 0 to 125. However, P.S. 2 due to pain from lytic bone lesions is acceptable 8. Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung, liver, and kidney functions) * Neutrophil count:≥ 1,500 /mm\^3 * Platelet count:≥ 75,000 /mm\^3 * Albumin:≥ 2.5 g /dL * Aspartate aminotransferase (AST) Glutamic oxaloacetic transaminase (GOT): \< than 3.0 times the upper limit of normal range for the site * Alanine aminotransferase (ALT) Glutamic pyruvic transaminase (GPT): \< than 3.0 times the upper limit of normal range for the site * Total bilirubin: \< than 1.5 times the upper limit of normal range for the site * Serum creatinine: \< than 3.0 times the upper limit of normal range for the site * Partial pressure of O2 (PaO2) ≥ 65 mmHg * No abnormalities which require treatment are detected on ECG * Left ventricular ejection fraction (LVEF)(echocardiography): ≥ 55% 9. Patients who have provided written consent for participation in this study Exclusion Criteria: 1. Patients with apparent infections (including viral infections) 2. Patients with serious complications (hepatic or renal dysfunction, etc.) 3. Patients with complications or medical history of serious cardiac disease (e.g., myocardial infarction, ischemic heart disease) within 2 years of the date of interim registration or patients with arrhythmias that require treatment 4. Patients with serious gastrointestinal symptoms (e.g., severe nausea, vomiting, or diarrhea) 5. Patients positive for Hepatitis B surface (HBs) antigen, Hepatitis C virus (HCV) antibody, or HIV antibody 6. Patients with serious bleeding tendencies (e.g., disseminated intravascular coagulation: DIC) 7. Patients with, or confirmed in the past to have had, interstitial pneumonia, pulmonary fibrosis, or pulmonary emphysema which requires treatment. 8. Patients with a complication of apparent cardiac amyloidosis 9. Patients with infiltration to the central nervous system (CNS) or patients with clinical symptoms of suspected infiltration to the CNS, 10. Patients with active multiple primary cancer 11. Patients with, or confirmed in the past to have had, autoimmune hemolytic anemia 12. Patients who have received this investigational product in the past 13. Patients who have received allogeneic stem cell transplants in the past. (patients who have received autologous stem cell transplantation are acceptable) 14. Patients who received cytokine preparations such as erythropoietin or granulocyte colony stimulating factor (G-CSF) or blood transfusions within 1 week prior to the examination conducted before interim registration for this study 15. Patients who received other investigational products or unapproved medications within 3 months before interim registration for this study 16. Patients with prior allergies to medications that are similar to this investigational product (e.g., alkylating agents, or purine-nucleoside derivatives) or mannitol 17. Patients with drug addiction, narcotics addiction, and/or alcohol dependency 18. Patients who are pregnant, who may possibly be pregnant, or lactating 19. Patients who do not agree to practice contraception for the following periods: Male: During investigational product administration and until 6 months after final administration Female: During investigational product administration and until 4 months after final administration 20. Patients otherwise judged by the investigator or sub-investigator to be unsuitable for inclusion in this study
maximum Age: 79 Years
minimum Age: 20 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

intervention Names
Drug: SyB L-0501
label
SyB L-0501
type
EXPERIMENTAL

interventions

arm Group Labels
SyB L-0501
description
The administration of SyB L-0501 at 90 mg/m\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
name
SyB L-0501
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 17
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The criteria for sCR, CR, VGPR, and PR based on IMWG are shown below. sCR: Fulfills CR criteria as well as all of the following conditions * Normal free light chain (FLC) ratio(κ/λ) * Disappearance of clonal cells in bone marrow by immunohistochemistry or immunofluorescence CR: Fulfills all of the following criteria * Negative immunofixation of serum and urine M-protein * \<5% plasma cells in bone marrow * Disappearance of any soft tissue plasmacytoma VGPR: Fulfills at least one of the following criteria * Serum and urine M-protein detectable by immunofixation but not electrophoresis * ≥90% reduction in serum M-protein and 24-hour M-protein excretion amount in urine \<0.1 g/24 hour PR: Fulfills the following criteria * ≥50% reduction in serum M-protein, and ≥90% reduction in urine M-protein, urine M-protein excretion amount is reduced to \< 0.2 g/24hours
measure
Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria
time Frame
up to around 44 weeks

secondary Outcomes

measure
Response Rate (sCR+CR) Based on IMWG Criteria
time Frame
up to around 44 weeks
description
The criteria for CR based on the Blade are shown below. CR requires all of the followings: 1. Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 weeks 2. \<5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy 3. No increase in size or number of lytic bone lesions 4. Disappearance of soft tissue plasmacytomas
measure
Complete Response (CR) Based on the Blade Criteria
time Frame
up to around 44 weeks
description
The criteria for PR based on the Blade are shown below. PR requires 1. or all of the others: 1. Some, but not all, of the criteria for CR are fulfilled 2. ≥50% reduction in the level of the serum monoclonal paraprotein, maintained for a minimum of 6 weeks 3. Reduction in 24 h urinary light chain excretion either by ≥90% or to \<200 mg, maintained for a minimum of 6 weeks 4. For patients with non-secretory myeloma only, ≥50% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy 5. ≥50% reduction in the size of soft tissue plasmacytomas 6. No increase in size or number of lytic bone lesions
measure
Response Rate (CR+PR) Based on the Blade Criteria
time Frame
up to around 44 weeks
description
Using the registration date as the start date, PFS with relapse/recurrence or progression, and death regardless of the cause as events are to be summarized using the Kaplan-Meier estimator and the 50% point according to the Greenwood's formula and the 95% confidence interval are to be calculated.
measure
Progression-Free Survival (PFS)
time Frame
up to around 44 weeks
description
Using the registration date as the start date, TTF with relapse/recurrence or progression, death regardless of the cause, and early discontinuation of treatment as events are to be summarized using the Kaplan-Meier estimator and the 50% point according to the Greenwood's formula and 95% confidence interval are to be calculated.
measure
Time to Treatment Failure (TTF)
time Frame
up to around 44 weeks
description
From initial response (PR or higher), DOR with relapse/recurrence or progression, and death, regardless of cause, as events, are to be summarized using the Kaplan-Meier estimator and the 50% point according to the Greenwood's formula and 95% confidence interval are to be calculated.
measure
Duration of Response (DOR)
time Frame
up to around 44 weeks
description
Using the registration date as the start date, OS with death, regardless of the cause, as events, are to be summarized using the Kaplan-Meier estimator and the 50% point according to the Greenwood's formula and 95% confidence interval are to be calculated.
measure
Overall Survival (OS)
time Frame
up to around 44 weeks
description
All adverse events occurring during the administration of the investigational product are to be examined for safety by cross tabulation lists and tables of incidence from the viewpoint of relationship with the drug, disease severity and medicine treated group.
measure
Adverse Events
time Frame
up to around 44 weeks
description
Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using Common Terminology Criteria for Adverse Events (CTCAE). grade 1 : mild, grade 2 : moderate, grade 3 : severe or medically significant but not immediately life-threatening grade, 4 : life threatening or disabling grade, 5 : death related to adverse event
measure
Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values
time Frame
up to around 44 weeks
description
Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using Common Terminology Criteria for Adverse Events (CTCAE). grade 1 : mild, grade 2 : moderate, grade 3 : severe or medically significant but not immediately life-threatening grade, 4 : life threatening or disabling grade, 5 : death related to adverse event
measure
Number of Abnormalities (Grade ≥3) in Laboratory Test Values
time Frame
up to around 44 weeks

Full study description

brief Summary: The purpose of this study is to determine the antitumor efficacy and safety of bendamustine (SyB L-0501: 90 mg/m\^2/day) for a maximum of 6 cycles (1 cycle: intravenous administration for 2 consecutive days and 26-day observation period) in patients with relapsed/refractory multiple myeloma.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-106cf0d1c5358109cb49
requested nct id
NCT01849848
primary nct id
NCT01849848
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
6d642588a48914735f9db67bb1f787d30871a58122611e5515a762b289a19986
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-106cf0d1c5358109cb49
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01849848
occurrences
context exact
NCT01849848
end
11
exact text
NCT01849848
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/593/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
3cd6d960c3b61c484292678d7c2f1e7cb6b319f6d486f60e8708ef3f58ea5398
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice